Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Raised by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.9% during the fourth quarter, Holdings Channel reports. The firm owned 372,452 shares of the biopharmaceutical company’s stock after purchasing an additional 42,554 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Gilead Sciences were worth $30,172,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of GILD. Independent Advisor Alliance lifted its stake in Gilead Sciences by 118.4% during the third quarter. Independent Advisor Alliance now owns 14,378 shares of the biopharmaceutical company’s stock valued at $1,077,000 after buying an additional 7,794 shares in the last quarter. Mastrapasqua Asset Management Inc. lifted its position in shares of Gilead Sciences by 3.5% in the 3rd quarter. Mastrapasqua Asset Management Inc. now owns 4,316 shares of the biopharmaceutical company’s stock valued at $323,000 after acquiring an additional 145 shares in the last quarter. Telemus Capital LLC grew its position in Gilead Sciences by 379.4% during the 3rd quarter. Telemus Capital LLC now owns 17,801 shares of the biopharmaceutical company’s stock worth $1,334,000 after purchasing an additional 14,088 shares in the last quarter. Concord Wealth Partners raised its stake in Gilead Sciences by 47.1% during the 3rd quarter. Concord Wealth Partners now owns 13,671 shares of the biopharmaceutical company’s stock valued at $1,025,000 after purchasing an additional 4,376 shares during the period. Finally, Verdence Capital Advisors LLC lifted its holdings in shares of Gilead Sciences by 18.2% in the third quarter. Verdence Capital Advisors LLC now owns 13,426 shares of the biopharmaceutical company’s stock valued at $1,006,000 after purchasing an additional 2,069 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Trading Down 0.8 %

Gilead Sciences stock opened at $64.78 on Friday. Gilead Sciences, Inc. has a one year low of $64.33 and a one year high of $87.86. The company’s fifty day moving average price is $70.55 and its two-hundred day moving average price is $75.83. The company has a debt-to-equity ratio of 1.08, a current ratio of 0.98 and a quick ratio of 0.72. The company has a market capitalization of $80.66 billion, a price-to-earnings ratio of 179.94, a PEG ratio of 1.30 and a beta of 0.22.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The company had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. During the same quarter in the prior year, the company posted $1.37 EPS. The firm’s revenue was up 5.3% on a year-over-year basis. On average, analysts forecast that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be issued a dividend of $0.77 per share. The ex-dividend date is Friday, June 14th. This represents a $3.08 annualized dividend and a yield of 4.75%. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on GILD. Wells Fargo & Company lowered their price target on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a report on Monday, March 4th. TD Cowen lowered their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Friday, April 26th. Royal Bank of Canada reduced their price target on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating for the company in a research report on Friday, April 26th. Maxim Group lowered their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Morgan Stanley cut their target price on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research report on Friday, April 26th. Eleven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $83.69.

Insider Activity

In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.